Skip to main content
Deniz Can Guven on Muck Rack

Deniz Can Guven

As seen in: Nature, Wiley Online Library, Frontiers, MDPI, South China Morning Post, Taylor & Francis Online, BMC Cancer, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Deniz Can

Contact Deniz Can, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

|
By Muhammet Cengiz, Oktay Bozkurt, Ayşe Cengiz, Deniz Can Guven, Elif Tugba Sahin, Elif Ayça Şahin, Mustafa Ersoy, Sedat Yildirim, Beyza Ünlü, Hayati Arvas, Mehmet Mutlu Kidi, Sedat Biter, Mustafa Erman, İsmail Kara, Umut Kefeli, Saadettin Kilickap, Teoman Şakalar, Berrak Mermit Ercek, Havva Yesil Cinkir, Metin Ozkan, Emel Mutlu Ozkan, Ezgi Turkoğlu, Erdem Kolemen, Latif Karahan, Meltem Baykara, Pervin Can Sanci, Anıl Karakayali, Devrim Cabuk, Nargiz Majidova, Muslih Urun, Gözde Agdas, Duygu Bayir, Cengiz Akosman, Erkam Kocaaslan, Mevlude Inanc
| Nature Verified
Abstract Nivolumab is currently widely used in the treatment of lung cancer. Studies have been conducted using flat doses of 240 mg and 3 mg/kg. In fact, studies involving a small number of patients have begun to explore low-dose immunotherapies. The literature on the optimal dose of immunotherapy, the use of weight based, or fixed doses is very recent and has become a one of the subject of ongoing research. This multicenter study included 716 patients with NSCLC.
Open in Who Shared Issue with article?

Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross‐Sectional Study

|
By Taha Koray Sahin, Ezgi Sahin, Hande Güngör, Deniz Can Guven
| Wiley Online Library Verified
1 Introduction Lymphomas represent a heterogeneous group of malignant lymphoid neoplasms with significantly different prognosis and treatment and are broadly categorized into two groups: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) [1]. With the advent of novel treatment options, the 5-year relative survival rate has reached over 90% for HL and about 80% for NHL. However, approximately 30%–40% of patients with lymphoma eventually experience recurrence [2, 3].
Open in Who Shared Issue with article?

Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors

|
By Taha Koray Sahin, Sercan Aksoy, Deniz Can Guven
| Taylor & Francis Online
ABSTRACT Introduction Hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC) remains a prevalent and challenging disease. Endocrine therapy (ET) combined with CDK4/6 inhibitors is the first-line standard of care, yet resistance mechanisms, including ESR1 mutations, drive disease progression. Novel oral selective estrogen receptor degraders (SERDs) have emerged as promising therapeutic agents after progression with CDK4/6 inhibitors secondary to ESR1 mutations.
Open in Who Shared Issue with article?
See all 25 licensed articles (26 Total)